Lipid nanoparticles (LNPs) have become the gold standard in non-viral gene delivery technologies, exemplified by the approval of the LNP messenger RNA (mRNA) vaccines against SARS-CoV-2. Since then, ...

Certest Pharma specializes in advanced lipid nanoparticle technology, focusing on the development of effective and targeted LNPs for next-generation medicines. Certest’s licensable technology includes ...

Researchers at Ludwig Maximilian University of Munich developed hybrid PLGA-PBAE nanoparticles that delivered mRNA vaccines ...

Lipid nanoparticles (LNPs) have enormous potential for the delivery of genomic medicine. One obstacle, however, is the lack of effective ways to target specific cell types. In order to target lung ...

Two biotechs are teaming up to deliver cholesterol-busting mRNA to clogged arteries. Syracuse, New York-based Repair Biotechnologies will use Swiss company Genevant’s lipid nanoparticles to usher its ...

The findings, demonstrated in mouse models and isolated human brain tissue, could expand treatment options for neurological and psychiatric diseases. (Nanowerk News) Scientists at the Icahn School of ...

insights from industryYoann LefeuvreDirector of Product ManagementMicrotrac In this interview, AZoNano speaks with Yoann Lefeuvre, Director of Product Management at Microtrac. Yoann discusses ...

Örn Almarsson is the Co-Founder and CEO of a startup biopharma company called Axelyf (Hafnarfjörður, Iceland & MA, USA) that is developing lipid technologies to safely and efficiently deliver mRNA ...

Northwestern University has filed a patent infringement lawsuit against Moderna, Inc. (NASDAQ:MRNA), alleging the pharmaceutical company used the university’s lipid nanoparticle (LNP) technology ...

Malvern Panalytical’s recent peer-reviewed publication, Tailoring Lipid Nanoparticle Dimensions Through Manufacturing Processes, published in RSC Pharmaceutics, features both the NanoSight Pro ...